Celgene profit beats estimates as demand for cancer drugs rise

April 25 Thu Apr 25, 2013 7:41am EDT

April 25 (Reuters) - Biotechnology firm Celgene Corp reported a first-quarter profit that edged past analysts' estimates on strong demand for its cancer drugs, Revlimid and Abraxane, and it raised its 2013 earnings forecast.

Net income fell to $384.9 million, or 89 cents per share, from $401.5 million, or 90 cents per share, a year earlier.

Excluding one-time items, it earned $1.37 per share. Analysts on average expected a profit of $1.35 per share, according to Thomson Reuters I/B/E/S.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.